Fast Fault Location Method for a Distribution System with High Penetration of PV

Distribution systems with high levels of solar PV may experience notable changes due to external conditions, such as temperature or solar irradiation. Fault detection methods must be developed in order to support these changes of conditions. This paper develops a method for fast detection, location, and classification of faults in a system with a high level of solar PV. The method uses the Continuous Wavelet Transform (CWT) technique to detect the traveling waves produced by fault events. The CWT coefficients of the current waveform at the traveling wave arrival time provide a fingerprint that is characteristic of each fault type and location. Two Convolutional Neural Networks are trained to classify any new fault event. The method relays of several protection devices and doesn’t require communication between them. The results show that for multiple fault scenarios and solar PV conditions, high accuracy for both location and type classification can be obtained

Effects of Caffeine on Perceptually-Based Intensity Production During Outdoor Running

ABSTRACT International Journal of Exercise Science 12(5): 526-535, 2019. Caffeine (CAF) may enhance performance while altering estimated RPE. However, effects of caffeine on RPE production is not well understood. This study examined effects of CAF on velocity (VEL) selection during outdoor running when intensity was prescribed using RPE. Ten (n = 10) fit male runners completed a VO2 max and two running trials, CAF (6 mg· kg-1) vs. placebo (PLA). Participants ran a 2.4 km (1.5 m) bout, at prescribed RPE4, and another at prescribed RPE7, following 10 min passive recovery. Separate 2 (trial) x 6 (time point) repeated measures ANOVA’s compared CAF vs. PLA for VEL and heart rate (HR). No significant main effect was found (CAF vs. PLA) for VEL (m∙min-1) for RPE4 (CAF: 201.7 ± 25.8 vs. PLA: 196.0 ± 17.5) (p = 0.29) or RPE7 (CAF: 236.7 ± 19.5 vs. PLA 231.8 ± 21.3) (p = 0.30). Similarly, no main effect was found (CAF vs. PLA) for HR for RPE4 (CAF: 163 ± 12 vs. PLA: 162 ± 14) (p = 0.69) or RPE7 (CAF: 181 ± 7 vs. PLA: 178 ± 10) (p = 0.31). No significant difference was found for Session-RPE for RPE4 (CAF: 4.0 ± 0.00, PLA: 4.20 ± 0.42) (p = 0.17), however, Session-RPE for RPE7 CAF (7.10± 0.32) was significantly lower than PLA (7.50 ± 0.53) (p = 0.04). While group means show no significant differences, 9 of 20 total trials (45%) were 26 to 104 sec faster for CAF (mean difference = 54 sec) demonstrating improvement in select individuals. Future research should focus on varying responses of individuals to CAF

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Effects of Magnesium Supplementation on Muscle Soreness and Performance

This double-blind, between-group study examined effects of magnesium (Mg) supplementation (350 mg·d−1, 10 days) on muscle soreness and performance. College-aged male (n = 9) and female (n = 13) subjects completed baseline and posttreatment eccentric bench press sessions inducing fatigue/soreness followed by performance sessions (total volume and repetitions to failure [RTF] [65, 75, and 85% of 1 repetition maximum]) 48 hours later with perceptual measures. Subjects estimated soreness using a Delayed Onset of Muscle Soreness scale by striking a vertical line on a 6-cm horizontal line (at 24, 36, and 48 hours post trial) from 0—no soreness to 6—intolerable soreness. Results are presented as means ± SD (alpha ≤0.05). Mg significantly reduced (∼1–2 units lower on a 6-point scale) muscle soreness from the baseline eccentric to postintervention trial 24, 36, and 48 hours with no significant change for placebo (Pla) group. Performance approached significance for total RTF (p = 0.06) and 65 and 75% RTF (p = 0.08) (Mg vs. Pla). Perceptual responses for session rating of perceived exertion and acute rating of perceived exertion were significant for Mg (5.1 ± 2.4 to 4.1 ± 2.0) vs. Pla (5.0 ± 1.8 to 5.5 ± 1.6). Perceived recovery after supplementation was improved vs. baseline for Mg (5.4 ± 2.2 to 7.5 ± 2.3) but not for Pla (6.2 ± 2.4 to 7.2 ± 3.3). Results show significantly reduced muscle soreness, session rating of perceived exertion, acute rating of perceived exertion, and improved perceived recovery after Mg (vs. Pla) supplementation and some evidence for positive performance impact

A facility to search for hidden particles at the CERN SPS: the SHiP physics case.

The standard model of elementary particle physics has provided a consistent description of Nature's fundamental constituents and their interactions. Its predictions have been tested and confirmed by numerous experiments. The Large Hadron Collider's runs at 7 and 8 TeV culminated in the discovery of a Higgs boson-like particle with the mass of about 126 GeV—the last critical standard model component [1–5]. Thus for the first time we are in the situation when all the particles, needed to explain the results of all previous accelerator experiments have been found. At the same time, no significant deviations from the standard model were found in direct or in indirect searches for new physics (see e.g. the summary of the recent search results in [6–25] and most up-to-date information at [26–29]). For this particular value of the Higgs mass it is possible that the standard model remains mathematically consistent and valid as an effective field theory up to a very high energy scale, possibly all the way to the scale of quantum gravity, the Planck scale [30–32]

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

International audienc